



The apoA-I companY

Press Release

ABIONYX Pharma Announces Its Combined Annual Shareholders' Meeting on Tuesday, June 30, 2026

Toulouse, FRANCE, Fullerton, UNITED STATES, June 26, 2026, 6:00 p.m. CEST – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME-eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, informs its shareholders that its Combined Annual General Meeting will be held on Tuesday, June 30, 2026, at 4:00 p.m. at the Company's headquarters at 33-43 avenue Georges Pompidou – Building D, in Balma (31130), France.

In accordance with the notice of meeting published in the Bulletin des Annonces Légales Obligatoires (BALO), shareholders will be asked to vote on resolutions falling under both the ordinary and extraordinary powers of the Meeting. These resolutions pertain, in particular, to the approval of the financial statements for fiscal year 2025, the Company's governance, compensation policies, the renewal of certain terms of office, as well as various financial authorizations.

The Board of Directors invites all shareholders to participate in this General Meeting, a valuable opportunity to discuss the Company's strategy, achievements, and growth prospects.

The preparatory documents for the Annual General Meeting, including the agenda, the text of the resolutions, and the procedures for participation and voting, are made available to shareholders in accordance with applicable regulations.

In accordance with Articles L. 22-10-38-1 and R. 22-10-29-1 of the French Commercial Code, the Meeting will be broadcast live in its entirety via the following link: <https://abionyx.clickmeeting.com/abionyx-pharma-assemblee-generale>

A recording of the Meeting will be available on the Company's website no later than seven business days after the date of the Meeting and for at least two years from the date it is posted online.

The Board of Directors thanks all of its shareholders for their trust and support in advancing ABIONYX Pharma's development strategy.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious diseases for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biopharmaceuticals and next-generation HDL vectors that target the immune-inflammatory dysregulation at the heart of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.

Contacts:

ABIONYX Pharma
infos@abionyx.com

Disclaimer:

The statements contained in this document may constitute “forward-looking statements.” These statements include all matters that are not historical facts and can generally, but not always, be identified by the use of words such as “believes,” “expects,” “should,” “anticipates,” “intends to,” “estimates,” “is expected to,” “will continue to,” “may,” “is likely to,” “forecasts,” or similar expressions, including their variations, negative forms, or comparable terms.

Forward-looking statements are not guarantees of future performance; they involve a number of known and unknown risks, uncertainties, and other factors, and ABIONYX Pharma’s actual operating results, financial condition, and the development of the industry in which it operates may differ materially from those indicated or suggested by the forward-looking statements contained in this document. Furthermore, even if ABIONYX Pharma’s operating results and financial condition, as well as developments in the industry in which it operates, are consistent with the forward-looking statements contained in this document, such results or developments are not necessarily indicative of results or developments in subsequent periods. ABIONYX Pharma does not undertake to publicly update or revise any forward-looking statements that may be made in this document, whether as a result of new information, future events, or otherwise.